Antengene Advances Novel ADC, TCE Programs with AACR 2026 Data
Event summary
- Antengene presented preclinical data at AACR 2026 for three novel programs: ATG-125 (B7-H3 x PD-L1 ADC), ATG-106 (CDH6 x CD3 TCE), and ATG-112 (ALPPL2 x CD3 TCE).
- ATG-125 demonstrated synergistic antitumor activity in xenograft models, combining direct tumor killing with immune activation.
- ATG-106, a sterically masked TCE, showed potent cytotoxicity and limited cytokine release in ovarian and kidney cancer models.
- ATG-112, targeting ALPP/G, exhibited robust antitumor activity with minimal cytokine release in humanized mouse models.
The big picture
Antengene's AACR presentations underscore the continued innovation in targeted cancer therapies, specifically in the burgeoning fields of antibody-drug conjugates and T cell engagers. The company's AnTenGager® platform represents a strategic bet on a next-generation TCE approach designed to mitigate the risks associated with earlier-generation therapies. The success of these programs will be critical for Antengene's long-term growth and its ability to compete in a rapidly evolving oncology market.
What we're watching
- Clinical Translation
- The success of these preclinical programs hinges on translating the observed efficacy and safety profile to human clinical trials, particularly regarding cytokine release syndrome with the TCE candidates.
- Platform Scalability
- Antengene's AnTenGager® platform's versatility will be tested as they expand its application to additional targets and indications beyond the three programs highlighted.
- Competitive Landscape
- The ADC and TCE fields are increasingly crowded; Antengene will need to demonstrate a clear advantage in terms of efficacy, safety, or intellectual property to secure market share.
Related topics